According to the app of Wisdom Finance, Akeso (09926) rose more than 3% in the afternoon. As of press time, it fell by 3.01% and reported HKD 39.4 with a turnover of HKD 88.2933 million.

Morgan Stanley released a report that states that Edafy, which has been approved by the National Medical Products Administration for the sale of new drugs, and has outperformed Pembrolizumab in the III Phase head-to-head study of drugs. This achievement is historic. The bank believes that Summit Therapeutics, the cooperation partner in the United States, has risen by 204% this year, while the stock price of Akeso has fallen by 23% during the same period. The bank believes that the diverging stock price trend provides a buying opportunity.

In addition, according to the industry media Yaofang.com's report, as the national medical insurance negotiation for 2024 enters the preparation phase, Akeso has lowered the price of its double antibody new drug, Cardinale monoclonal antibody. Its unit price has been reduced from CNY 13,220/125mg/bottle to CNY 6,166/125mg/bottle, a decrease of 53.4%. On the same day, Akeso confirmed this price and cancelled the gift of medicine to patients with Interface News, stating that the new price will give patients greater flexibility in purchasing medicine, and that they will actively participate in this year's medical insurance negotiation.